PIMAVANSERIN TARTRATE

Pimavanserin Tartrate is an atypical antipsychotic that acts as a selective serotonin inverse agonist and antagonist at the 5-HT2A receptors. It is primarily used to treat psychosis associated with Parkinson’s disease.

Indications

-Treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. -Investigated for potential use in other neuropsychiatric disorders such as schizophrenia and dementia-related psychosis.

Dosage

-The typical adult dose for Parkinson’s disease psychosis is 34 mg once daily (equivalent to 40 mg of Pimavanserin). -Can be taken with or without food. -Dosage adjustments may be required in patients with renal or hepatic impairment.

Contra-Indications

-Hypersensitivity to Pimavanserin or any of its components. -Patients with severe hepatic impairment. -Not recommended for use in patients with QT prolongation or those taking medications that significantly prolong the QT interval.

Special Precautions

-QT Prolongation: May increase the risk of arrhythmia; caution in patients with cardiac conditions. -Elderly Patients with Dementia-Related Psychosis: Increased mortality risk; not approved for dementia-related psychosis. -Renal or Hepatic Impairment: Dose adjustments may be necessary. -Suicidal Thoughts & Behavior: Monitor patients for signs of worsening psychiatric symptoms.

Side Effects

-Common: Nausea, peripheral edema, confusion, hallucinations, dizziness. -Serious: QT prolongation, cardiac arrhythmia, worsening psychotic symptoms, hypersensitivity reactions.